Cogent Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Cogent Biosciences

05/08/2025 15:58

Cogent Biosciences Inc COGT.OQ reported a quarterly adjusted loss of 53 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -59 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -66 cents to -46 cents per share.

Reported revenue was zero​; analysts expected zero.

Cogent Biosciences Inc's reported EPS for the quarter was a loss of 64 cents​.

The company reported a quarterly loss of $73.53 million.

Cogent Biosciences Inc shares had risen by 67.8% this quarter and gained 54.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cogent Biosciences Inc is $19.00, about 36.6% above its last closing price of $12.05

This summary was machine generated from LSEG data August 5 at 02:57 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.58
-0.53
Beat
Mar. 31 2025
-0.59
-0.52
Beat
Dec. 31 2024
-0.59
-0.12
Beat
Sep. 30 2024
-0.57
-0.64
Missed